title: Thromboprophylaxis in multiple myeloma: is the evidence there?
authors.forename: Sigurdur Yngvi
authors.initials: SY
authors.lastname: Kristinsson
authors.forename: Ola
authors.initials: O
authors.lastname: Landgren
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D056747:Immunomodulation; D009101:Multiple Myeloma / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D020379:Risk Adjustment; D055502:Secondary Prevention / Q000379:methods; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects*; D054556:Venous Thromboembolism / Q000209:etiology / Q000517:prevention & control; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D013792:Thalidomide; D014859:Warfarin; D001241:Aspirin